This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Grifols Announces New North American Commercial Operations Organization

Stocks in this article: GRFGRFS

LOS ANGELES, Aug. 2, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, has announced the structure of its new North American Commercial Operations.  Under the new Commercial Operations structure, the U.S. commercial group will be organized by product portfolio to better serve patients and customers throughout North America.  The Canadian organization, a major presence within North American operations, will remain structurally unchanged.

(Logo:   http://photos.prnewswire.com/prnh/20110304/PH59473LOGO )

"By creating cross-functional teams for the major product areas, the sales, marketing, and business functions can work more closely together toward customer-specific goals and objectives," said Gregory Rich, President and CEO of Grifols' North American operations. "This will provide greater focus for our teams and permit us to build upon our existing customer partnerships as well as establish new ones," continued Mr. Rich.  Dedicated national accounts and managed care teams will complement the product portfolio-based sales and marketing teams.  

Joel Abelson will serve as the president of Grifols' North American Commercial Operations.  Mr. Abelson was formerly head of Talecris' International Commercial Operations.  In his new position, he will oversee the marketing and sales strategy for all of Grifols' North American products.  Mr. Abelson has nearly 20 years of senior management experience in the healthcare industry and was responsible for Talecris' commercial operations in all markets outside of the United States and Europe.

Grifols' North American Commercial Operations will be supported by a team of experienced professionals with a proven track record of meeting patient and customer needs in the plasma therapeutics industry and the general healthcare arena.

  • Bill Zabel, Vice President and General Manager of IVIG/Albumin/Hypermune Products  

Mr. Zabel has more than 20 years of healthcare leadership experience, and he has worked in the biological therapeutics industry for more than a decade.  He previously served as Talecris' U.S. Vice President of Sales and held senior commercial positions in Bayer Healthcare Corporation.

  • Whitney Herd, Vice President and General Manager of Hematology/Diagnostics/Hospital Products  

Ms. Herd has nearly 16 years of healthcare leadership experience working both in biopharmaceutical and diagnostic companies.  Ms. Herd previously served as Vice President and General Manager of Grifols U.S. Bioscience portfolio.

  • Lafmin Morgan, Vice President and General Manager of Pulmonary Products

Mr. Morgan previously served as Talecris' Vice President of U.S. Product Management.  He joined the organization in 2010 from GlaxoSmithKline, where he served twenty years in various finance, sales, commercial strategy, and marketing roles across a variety of therapeutic areas.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs